Edition:
United Kingdom

Alkermes Plc (ALKS.OQ)

ALKS.OQ on NASDAQ Stock Exchange Global Select Market

40.16USD
19 Oct 2018
Change (% chg)

$-0.64 (-1.57%)
Prev Close
$40.80
Open
$40.87
Day's High
$41.86
Day's Low
$39.86
Volume
356,536
Avg. Vol
264,840
52-wk High
$71.22
52-wk Low
$38.23

Latest Key Developments (Source: Significant Developments)

FDA Approves ARISTADA INITIO For Initiation Of Aristada® For Schizophrenia
Monday, 2 Jul 2018 

July 2 (Reuters) - Alkermes Plc ::FDA APPROVES ARISTADA INITIO™ FOR THE INITIATION OF ARISTADA® FOR SCHIZOPHRENIA.ALKERMES PLC - ARISTADA INITIO IS EXPECTED TO BE AVAILABLE IN MID-JULY.  Full Article

Alkermes Says Receives $50 Million Payment From Biogen
Wednesday, 6 Jun 2018 

June 6 (Reuters) - Alkermes Plc ::ALKERMES RECEIVES $50 MILLION PAYMENT FROM BIOGEN FOLLOWING REVIEW OF PRELIMINARY GASTROINTESTINAL TOLERABILITY DATA FROM THE ONGOING BIIB098 CLINICAL DEVELOPMENT PROGRAM.ALKERMES PLC - ALKERMES EXPECTS TO SUBMIT A NEW DRUG APPLICATION (NDA) FOR BIIB098 TO U.S. FOOD AND DRUG ADMINISTRATION (FDA) IN Q4 OF 2018.ALKERMES PLC - ALL OF PAYMENT WILL BE RECORDED AS LICENSE REVENUE IN ALKERMES' FINANCIAL RESULTS FOR QUARTER ENDING JUNE 30, 2018.ALKERMES - MAY ALSO RECEIVE $150 MILLION MILESTONE PAYMENT FROM BIOGEN UPON FDA APPROVAL, ON OR BEFORE DEC. 31, 2021, OF NDA FOR BIIB098.  Full Article

Alkermes Q1 GAAP Loss Per Share $0.40
Thursday, 26 Apr 2018 

April 26 (Reuters) - Alkermes Plc ::REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 NON-GAAP LOSS PER SHARE $0.09.Q1 GAAP LOSS PER SHARE $0.40.Q1 REVENUE $225.2 MILLION VERSUS I/B/E/S VIEW $219.3 MILLION.Q1 EARNINGS PER SHARE VIEW $-0.07 -- THOMSON REUTERS I/B/E/S.SEES FY 2018 LOSS PER SHARE $1.35 TO $1.55.COMPANY CONTINUES TO EXPECT TOTAL REVENUES TO RANGE FROM $975 MILLION TO $1.025 BILLION FOR FY18.NOW EXPECTS SG&A EXPENSES TO RANGE FROM $515 MILLION TO $545 MILLION FOR 2018.NOW EXPECTS SHARE-BASED COMPENSATION OF APPROXIMATELY $120 MILLION FOR 2018.COMPANY NOW EXPECTS NON-GAAP BASIC AND DILUTED LOSS PER SHARE OF $0.06 TO A NON-GAAP DILUTED EARNINGS PER SHARE OF $0.12 FY18.CONTINUES TO EXPECT CAPITAL EXPENDITURES TO RANGE FROM $80 MILLION TO $90 MILLION FOR 2018.Q1 EARNINGS PER SHARE VIEW $-0.07, REVENUE VIEW $219.3 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Alkermes Announces FDA Acceptance For Review Of New Drug Application For Alks 5461
Monday, 16 Apr 2018 

April 16 (Reuters) - Alkermes Plc ::ALKERMES ANNOUNCES FDA ACCEPTANCE FOR REVIEW OF NEW DRUG APPLICATION FOR ALKS 5461 FOR THE ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER.ALKERMES PLC - FDA ACTION EXPECTED BY JAN. 31, 2019.ALKERMES - ALKS 5461 NDA FILING BASED ON RESULTS FROM A CLINICAL EFFICACY AND SAFETY PACKAGE.  Full Article

Primecap Management Co Reports A 11.35 Pct Passive Stake In Alkermes
Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - Alkermes Plc ::PRIMECAP MANAGEMENT CO REPORTS A 11.35 PCT PASSIVE STAKE IN ALKERMES PLC <<>> AS OF NOV 30 - SEC FILING.  Full Article

Alkermes Expects 2017 Non-GAAP Income Of $0.03 To $0.22/Shr
Monday, 27 Nov 2017 

Nov 27 (Reuters) - Alkermes Plc ::ALKERMES PLC- NOW EXPECTS 2017 TOTAL REVENUES TO RANGE FROM $870 MILLION TO $900 MILLION‍​ - SEC FILING.ALKERMES PLC- NOW EXPECTS 2017 NON-GAAP DILUTED INCOME PER SHARE OF $0.03 TO $0.22.ALKERMES PLC - EXPECTS 2017 GAAP BASIC AND DILUTED LOSS PER SHARE OF $0.91 TO $1.10‍​.  Full Article

Alkermes’ NDA for ARISTADA accepted for filing by U.S. FDA
Thursday, 16 Nov 2017 

Nov 16 (Reuters) - Alkermes Plc ::Alkermes’ New Drug Application for Investigational Product Designed for Initiation Onto ARISTADA® accepted for filing by U.S. FDA.Says FDA issued target action date for Aripiprazole Lauroxil Nanocrystal Dispersion​ NDA of June 30, 2018 under PDUFA.  Full Article

ALKERMES INITIATES CLINICAL STUDY EVALUATING ARISTADA, INVEGA SUSTENNA FOR SCHIZOPHRENIA
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Alkermes Plc :ALKERMES TO INITIATE NEW CLINICAL STUDY EVALUATING ARISTADA® AND INVEGA SUSTENNA® FOR THE TREATMENT OF SCHIZOPHRENIA.ALKERMES PLC - ‍PHASE 3B STUDY WILL ASSESS INVESTIGATIONAL PRODUCT DESIGNED FOR INITIATION ONTO ARISTADA​.ALKERMES PLC - ‍EFFICACY AND SAFETY OF TWO-MONTH ARISTADA COMPARED TO MARKET LEADER INVEGA SUSTENNA WILL ALSO BE EVALUATED IN TRIAL​.  Full Article

ALKERMES PLC REPORTS ‍Q3 GAAP LOSS PER SHARE OF $0.24
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Alkermes Plc ::ALKERMES PLC REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS.‍Q3 TOTAL REVENUES INCREASED 21% YEAR-OVER-YEAR TO $217.4 MILLION​.‍Q3 GAAP LOSS PER SHARE OF $0.24​.‍Q3 NON-GAAP EARNINGS PER SHARE OF $0.03​.‍COMPANY UPDATES FINANCIAL EXPECTATIONS FOR 2017​.Q3 EARNINGS PER SHARE VIEW $-0.01, REVENUE VIEW $231.0 MILLION -- THOMSON REUTERS I/B/E/S.‍NOW EXPECTS 2017 TOTAL REVENUES TO RANGE FROM $850 MILLION TO $880 MILLION​.‍NOW EXPECTS 2017 BASIC AND DILUTED LOSS PER SHARE OF $1.04 TO $1.23​.‍NOW EXPECTS 2017 CAPITAL EXPENDITURES TO RANGE FROM $50 MILLION TO $60 MILLION, REDUCED FROM $70 MILLION TO $80 MILLION​.FY2017 EARNINGS PER SHARE VIEW $-0.04, REVENUE VIEW $894.3 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Alkermes PLC says ‍initiates rolling submission of ALKS 5461 NDA to U.S. FDA
Monday, 21 Aug 2017 

Aug 21 (Reuters) - Alkermes Plc : :Alkermes PLC- ‍Initiates rolling submission of ALKS 5461 NDA to U.S. FDA; Expects to complete submission of NDA for medicine by year-end 2017​.  Full Article

Oklahoma Medicaid tests new tactic to curb U.S. drug costs

LOS ANGELES, Aug 23 A new front in the battle over the cost of expensive medicines in the United States is opening up in Oklahoma, the first state where the government's Medicaid program is negotiating contracts for prescription drugs based on how well they work.